Pharmacogenetics of Drug-Induced QT Interval Prolongation: An Update

Drug Safety

Volumn 38, Issue 10, 2015, Pages 855-867

  Niemeijer, Maartje N ^a   van den Berg, Marten E ^a   Eijgelsheim, Mark ^a   Rijnbeek, Peter R ^a   Stricker, Bruno H ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Netherlands Health Care Inspectorate   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CITALOPRAM; CYTOCHROME P450; DOMPERIDONE; ERYTHROMYCIN; FLECAINIDE; MULTIDRUG RESISTANCE PROTEIN; NEURONAL NITRIC OXIDE SYNTHASE; POTASSIUM CHANNEL HERG; QUINOLONE DERIVATIVE;

CAUCASIAN; CONGENITAL HEART DISEASE; DRUG RESPONSE; ETHNIC DIFFERENCE; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; REVIEW; ADVERSE DRUG REACTION; ANIMAL; BRUGADA SYNDROME; CHEMICALLY INDUCED; GENETIC VARIATION; GENETICS; LONG QT SYNDROME; PROCEDURES;

ANIMALS; BRUGADA SYNDROME; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETIC VARIATION; HUMANS; LONG QT SYNDROME; PHARMACOGENETICS;

EID: 84942370415     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-015-0316-6     Document Type: Review

References (110)

1. Rijnbeek PR, van Herpen G, Bots ML, Man S, Verweij N, Hofman A, et al. Normal values of the electrocardiogram for ages 16–90 years. J Electrocardiol. 2014;47(6):914–21.
2. Committee for proprietary medicinal products. The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. 1997. http://www.fda.gov/ohrms/dockets/ac/03/briefing/pubs/cpmp.pdf. Accessed 13 Nov 2014.
3. Zipes DP, Wellens HJ. Sudden cardiac death. Circulation. 1998;98(21):2334–51.
4. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350(10):1013–22.
5. European Medicines Agency. ICH Topic E 14. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-arrhythmic drugs. 2005; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002879.pdf. Cited 2 Mar 2015.
6. Food and Drug Administration. International conference on harmonisation; guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Fed Regist. 2005;70(202):61134–5.
7. Kannankeril PJ, Roden DM. Drug-induced long QT and torsade de pointes: recent advances. Curr Opin Cardiol. 2007;22(1):39–43.
8. Kannankeril P, Roden DM, Darbar D. Drug-induced long QT syndrome. Pharmacol Rev. 2010;62(4):760–81.
9. Mahida S, Hogarth AJ, Cowan C, Tayebjee MH, Graham LN, Pepper CB. Genetics of congenital and drug-induced long QT syndromes: current evidence and future research perspectives. J Interv Card Electrophysiol. 2013;37(1):9–19.
10. Morita H, Wu J, Zipes DP. The QT syndromes: long and short. Lancet. 2008;372(9640):750–63.
11. Hong Y, Rautaharju PM, Hopkins PN, Arnett DK, Djousse L, Pankow JS, et al. Familial aggregation of QT-interval variability in a general population: results from the NHLBI Family Heart Study. Clin Genet. 2001;59(3):171–7.
12. Newton-Cheh C, Larson MG, Corey DC, Benjamin EJ, Herbert AG, Levy D, et al. QT interval is a heritable quantitative trait with evidence of linkage to chromosome 3 in a genome-wide linkage analysis: The Framingham Heart Study. Heart Rhythm. 2005;2(3):277–84.
13. Kannankeril PJ, Roden DM, Norris KJ, Whalen SP, George AL Jr, Murray KT. Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives. Heart Rhythm. 2005;2(2):134–40.
14. Arking DE, Pfeufer A, Post W, Kao WH, Newton-Cheh C, Ikeda M, et al. A common genetic variant in the NOS1 regulator NOS1AP modulates cardiac repolarization. Nat Genet. 2006;38(6):644–51.
15. Pfeufer A, Sanna S, Arking DE, Muller M, Gateva V, Fuchsberger C, et al. Common variants at ten loci modulate the QT interval duration in the QTSCD Study. Nat Genet. 2009;41(4):407–14.
16. Newton-Cheh C, Eijgelsheim M, Rice KM, de Bakker PI, Yin X, Estrada K, et al. Common variants at ten loci influence QT interval duration in the QTGEN Study. Nat Genet. 2009;41(4):399–406.
17. Post W, Shen H, Damcott C, Arking DE, Kao WH, Sack PA, et al. Associations between genetic variants in the NOS1AP (CAPON) gene and cardiac repolarization in the old order Amish. Hum Hered. 2007;64(4):214–9.
18. Aarnoudse AJ, Newton-Cheh C, de Bakker PI, Straus SM, Kors JA, Hofman A, et al. Common NOS1AP variants are associated with a prolonged QTc interval in the Rotterdam Study. Circulation. 2007;116(1):10–6.
19. Tobin MD, Kahonen M, Braund P, Nieminen T, Hajat C, Tomaszewski M, et al. Gender and effects of a common genetic variant in the NOS1 regulator NOS1AP on cardiac repolarization in 3761 individuals from two independent populations. Int J Epidemiol. 2008;37(5):1132–41.
20. Lehtinen AB, Newton-Cheh C, Ziegler JT, Langefeld CD, Freedman BI, Daniel KR, et al. Association of NOS1AP genetic variants with QT interval duration in families from the Diabetes Heart Study. Diabetes. 2008;57(4):1108–14.
21. Kapoor A, Sekar RB, Hansen NF, Fox-Talbot K, Morley M, Pihur V, et al. An enhancer polymorphism at the cardiomyocyte intercalated disc protein NOS1AP locus is a major regulator of the QT interval. Am J Hum Genet. 2014;94(6):854–69.
22. Kannankeril PJ. Understanding drug-induced torsades de pointes: a genetic stance. Expert Opin Drug Saf. 2008;7(3):231–9.
23. Shah RR. Drug-induced prolongation of the QT interval: why the regulatory concern? Fundam Clin Pharmacol. 2002;16(2):119–24.
24. Shah RR. Drug-induced QT interval prolongation: does ethnicity of the thorough QT study population matter? Br J Clin Pharmacol. 2013;75(2):347–58.
25. Woosley R. Drugs that prolong the QTc interval and/or induce torsade de pointes; Available from: http://www.crediblemeds.org/everyone/composite-list-all-qtdrugs. Cited 3 Mar 2015.
26. De Ponti F, Poluzzi E, Montanaro N. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience. Eur J Clin Pharmacol. 2000;56(1):1–18.
27. Johnson JA, Cavallari LH, Beitelshees AL, Lewis JP, Shuldiner AR, Roden DM. Pharmacogenomics: application to the management of cardiovascular disease. Clin Pharmacol Ther. 2011;90(4):519–31.
28. Aerssens J, Paulussen AD. Pharmacogenomics and acquired long QT syndrome. Pharmacogenomics. 2005;6(3):259–70.
29. Llerena A, Berecz R, Dorado P, de la Rubia A. QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. J Psychopharmacol. 2004;18(2):189–93.
30. Cartwright AL, Wilby KJ, Corrigan S, Ensom MH. Pharmacogenetics of risperidone: a systematic review of the clinical effects of CYP2D6 polymorphisms. Ann Pharmacother. 2013;47(3):350–60.
31. Potkin SG, Preskorn S, Hochfeld M, Meng X. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone. J Clin Psychopharmacol. 2013;33(1):3–10.
32. Llerena A, Berecz R, de la Rubia A, Dorado P. QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. J Psychopharmacol. 2002;16(4):361–4.
33. Desai M, Tanus-Santos JE, Li L, Gorski JC, Arefayene M, Liu Y, et al. Pharmacokinetics and QT interval pharmacodynamics of oral haloperidol in poor and extensive metabolizers of CYP2D6. Pharmacogenomics J. 2003;3(2):105–13.
34. Park JY, Shon JH, Kim KA, Jung HJ, Shim JC, Yoon YR, et al. Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. J Clin Psychopharmacol. 2006;26(2):135–42.
35. Thanacoody RH, Daly AK, Reilly JG, Ferrier IN, Thomas SH. Factors affecting drug concentrations and QT interval during thioridazine therapy. Clin Pharmacol Ther. 2007;82(5):555–65.
36. Ford GA, Wood SM, Daly AK. CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system. Br J Clin Pharmacol. 2000;50(1):77–80.
37. Owens RC Jr. QT prolongation with antimicrobial agents: understanding the significance. Drugs. 2004;64(10):1091–124.
38. Damle B, Fosser C, Ito K, Tran A, Clax P, Uderman H, et al. Effects of standard and supratherapeutic doses of nelfinavir on cardiac repolarization: a thorough QT study. J Clin Pharmacol. 2009;49(3):291–300.
39. Eap CB, Crettol S, Rougier JS, Schlapfer J, Sintra Grilo L, Deglon JJ, et al. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther. 2007;81(5):719–28.
40. Sakaeda T, Nakamura T, Okumura K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull. 2002;25(11):1391–400.
41. Verstuyft C, Schwab M, Schaeffeler E, Kerb R, Brinkmann U, Jaillon P, et al. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol. 2003;58(12):809–12.
42. Kurzawski M, Bartnicka L, Florczak M, Gornik W, Drozdzik M. Impact of ABCB1 (MDR1) gene polymorphism and P-glycoprotein inhibitors on digoxin serum concentration in congestive heart failure patients. Pharmacol Rep. 2007;59(1):107–11.
43. Aarnoudse AJ, Dieleman JP, Visser LE, Arp PP, van der Heiden IP, van Schaik RH, et al. Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration. Pharmacogenet Genomics. 2008;18(4):299–305.
44. Suzuki Y, Tsuneyama N, Fukui N, Sugai T, Watanabe J, Ono S, et al. Effect of risperidone metabolism and P-glycoprotein gene polymorphism on QT interval in patients with schizophrenia. Pharmacogenomics J. 2014;14(5):452–6.
45. Sissung TM, Gardner ER, Piekarz RL, Howden R, Chen X, Woo S, et al. Impact of ABCB1 allelic variants on QTc interval prolongation. Clin Cancer Res. 2011;17(4):937–46.
46. Paulussen AD, Gilissen RA, Armstrong M, Doevendans PA, Verhasselt P, Smeets HJ, et al. Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med (Berl). 2004;82(3):182–8.
47. Lehtonen A, Fodstad H, Laitinen-Forsblom P, Toivonen L, Kontula K, Swan H. Further evidence of inherited long QT syndrome gene mutations in antiarrhythmic drug-associated torsades de pointes. Heart Rhythm. 2007;4(5):603–7.
48. Aberg K, Adkins DE, Liu Y, McClay JL, Bukszar J, Jia P, et al. Genome-wide association study of antipsychotic-induced QTc interval prolongation. Pharmacogenomics J. 2012;12(2):165–72.
49. De Bruin ML, van Puijenbroek EP, Bracke M, Hoes AW, Leufkens HG. Pharmacogenetics of drug-induced arrhythmias: a feasibility study using spontaneous adverse drug reactions reporting data. Pharmacoepidemiol Drug Saf. 2006;15(2):99–105.
50. Itoh H, Sakaguchi T, Ding WG, Watanabe E, Watanabe I, Nishio Y, et al. Latent genetic backgrounds and molecular pathogenesis in drug-induced long-QT syndrome. Circ Arrhythm Electrophysiol. 2009;2(5):511–23.
51. Makita N, Horie M, Nakamura T, Ai T, Sasaki K, Yokoi H, et al. Drug-induced long-QT syndrome associated with a subclinical SCN5A mutation. Circulation. 2002;106(10):1269–74.
52. Ramirez AH, Shaffer CM, Delaney JT, Sexton DP, Levy SE, Rieder MJ, et al. Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes. Pharmacogenomics J. 2013;13(4):325–9.
53. Weeke P, Mosley JD, Hanna D, Delaney JT, Shaffer C, Wells QS, et al. Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome. J Am Coll Cardiol. 2014;63(14):1430–7.
54. Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation. 2002;105(16):1943–8.
55. Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ, et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci USA. 2000;97(19):10613–8.
56. Kaab S, Crawford DC, Sinner MF, Behr ER, Kannankeril PJ, Wilde AA, et al. A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ Cardiovasc Genet. 2012;5(1):91–9.
57. Hajj A, Ksouda K, Peoc’h K, Curis E, Messali A, Deveaux LL, et al. KCNH2 polymorphism and methadone dosage interact to enhance QT duration. Drug Alcohol Depend. 2014;1(141):34–8.
58. Vandenberg JI, Perry MD, Perrin MJ, Mann SA, Ke Y, Hill AP. hERG K(+) channels: structure, function, and clinical significance. Physiol Rev. 2012;92(3):1393–478.
59. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA. HERG, a human inward rectifier in the voltage-gated potassium channel family. Science. 1995;269(5220):92–5.
60. Rajamani S, Eckhardt LL, Valdivia CR, Klemens CA, Gillman BM, Anderson CL, et al. Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol. 2006;149(5):481–9.
61. Finlayson K, Witchel HJ, McCulloch J, Sharkey J. Acquired QT interval prolongation and HERG: implications for drug discovery and development. Eur J Pharmacol. 2004;500(1–3):129–42.
62. Drici MD, Barhanin J. Cardiac K+ channels and drug-acquired long QT syndrome. Therapie. 2000;55(1):185–93.
63. Crumb WJ Jr, Ekins S, Sarazan RD, Wikel JH, Wrighton SA, Carlson C, et al. Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis. Pharm Res. 2006;23(6):1133–43.
64. Sun Z, Milos PM, Thompson JF, Lloyd DB, Mank-Seymour A, Richmond J, et al. Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes. J Mol Cell Cardiol. 2004;37(5):1031–9.
65. Jonker DM, Kenna LA, Leishman D, Wallis R, Milligan PA, Jonsson EN. A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data. Clin Pharmacol Ther. 2005;77(6):572–82.
66. Barouch LA, Harrison RW, Skaf MW, Rosas GO, Cappola TP, Kobeissi ZA, et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature. 2002;416(6878):337–9.
67. Oceandy D, Cartwright EJ, Emerson M, Prehar S, Baudoin FM, Zi M, et al. Neuronal nitric oxide synthase signaling in the heart is regulated by the sarcolemmal calcium pump 4b. Circulation. 2007;115(4):483–92.
68. Splawski I, Timothy KW, Decher N, Kumar P, Sachse FB, Beggs AH, et al. Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations. Proc Natl Acad Sci USA. 2005;102(23):8089–96 (discussion 6–8).
69. Eijgelsheim M, Aarnoudse AL, Rivadeneira F, Kors JA, Witteman JC, Hofman A, et al. Identification of a common variant at the NOS1AP locus strongly associated to QT-interval duration. Hum Mol Genet. 2009;18(2):347–57.
70. Jamshidi Y, Nolte IM, Dalageorgou C, Zheng D, Johnson T, Bastiaenen R, et al. Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia. J Am Coll Cardiol. 2012;60(9):841–50.
71. van Noord C, Aarnoudse AJ, Eijgelsheim M, Sturkenboom MC, Straus SM, Hofman A, et al. Calcium channel blockers, NOS1AP, and heart-rate-corrected QT prolongation. Pharmacogenet Genomics. 2009;19(4):260–6.
72. Quraishi SA, Schuler GH, Janicki PK. 5 HT(3)-receptor antagonists and cardiac repolarization time in patients expressing a novel genetic target associated with baseline QTc interval abnormalities. J Clin Anesth. 2011;23(4):297–302.
73. Kanki H, Yang P, Xie HG, Kim RB, George AL Jr, Roden DM. Polymorphisms in beta-adrenergic receptor genes in the acquired long QT syndrome. J Cardiovasc Electrophysiol. 2002;13(3):252–6.
74. HapMap Project; Available from: http://www.hapmap.org. Cited 4 Mar 2015.
75. International HapMap C. The International HapMap Project. Nature. 2003;426(6968):789–96.
76. 1000 Genomes. A deep catalogue of human genetic variation; Available from: http://www.1000genomes.org. Cited 4 Mar 2015.
77. Genomes Project Consortium, Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, et al. A map of human genome variation from population-scale sequencing. Nature. 2010;467(7319):1061–73.
78. Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491(7422):56–65.
79. Daly AK. Genome-wide association studies in pharmacogenomics. Nat Rev Genet. 2010;11(4):241–6.
80. Behr ER, Ritchie MD, Tanaka T, Kaab S, Crawford DC, Nicoletti P, et al. Genome wide analysis of drug-induced torsades de pointes: lack of common variants with large effect sizes. PLoS One. 2013;8(11):e78511.
81. Volpi S, Heaton C, Mack K, Hamilton JB, Lannan R, Wolfgang CD, et al. Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry. 2009;14(11):1024–31.
82. Avery CL, Sitlani CM, Arking DE, Arnett DK, Bis JC, Boerwinkle E, et al. Drug-gene interactions and the search for missing heritability: a cross-sectional pharmacogenomics study of the QT interval. Pharmacogenomics J. 2014;14(1):6–13.
83. Florian JA, Tornoe CW, Brundage R, Parekh A, Garnett CE. Population pharmacokinetic and concentration—QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies. J Clin Pharmacol. 2011;51(8):1152–62.
84. Rautaharju PM, Prineas RJ, Kadish A, Larson JC, Hsia J, Lund B. Normal standards for QT and QT subintervals derived from a large ethnically diverse population of women aged 50 to 79 years [the Women’s Health Initiative (WHI)]. Am J Cardiol. 2006;97(5):730–7.
85. Fugate T 2nd, Moss AJ, Jons C, McNitt S, Mullally J, Ouellet G, et al. Long QT syndrome in African–Americans. Ann Noninvasive Electrocardiol. 2010;15(1):73–6.
86. Ackerman MJ, Splawski I, Makielski JC, Tester DJ, Will ML, Timothy KW, et al. Spectrum and prevalence of cardiac sodium channel variants among black, white, Asian, and Hispanic individuals: implications for arrhythmogenic susceptibility and Brugada/long QT syndrome genetic testing. Heart Rhythm. 2004;1(5):600–7.
87. Ackerman MJ, Tester DJ, Jones GS, Will ML, Burrow CR, Curran ME. Ethnic differences in cardiac potassium channel variants: implications for genetic susceptibility to sudden cardiac death and genetic testing for congenital long QT syndrome. Mayo Clin Proc. 2003;78(12):1479–87.
88. Splawski I, Timothy KW, Tateyama M, Clancy CE, Malhotra A, Beggs AH, et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science. 2002;297(5585):1333–6.
89. Anson BD, Ackerman MJ, Tester DJ, Will ML, Delisle BP, Anderson CL, et al. Molecular and functional characterization of common polymorphisms in HERG (KCNH2) potassium channels. Am J Physiol Heart Circ Physiol. 2004;286(6):H2434–41.
90. Shah SA, Herrington DM, Howard TD, Divers J, Arnett DK, Burke GL, et al. Associations between NOS1AP single nucleotide polymorphisms (SNPs) and QT interval duration in four racial/ethnic groups in the Multi-Ethnic Study of Atherosclerosis (MESA). Ann Noninvasive Electrocardiol. 2013;18(1):29–40.
91. Arking DE, Khera A, Xing C, Kao WH, Post W, Boerwinkle E, et al. Multiple independent genetic factors at NOS1AP modulate the QT interval in a multi-ethnic population. PLoS One. 2009;4(1):e4333.
92. Avery CL, Sethupathy P, Buyske S, He Q, Lin DY, Arking DE, et al. Fine-mapping and initial characterization of QT interval loci in African Americans. PLoS Genet. 2012;8(8):e1002870.
93. Smith JG, Avery CL, Evans DS, Nalls MA, Meng YA, Smith EN, et al. Impact of ancestry and common genetic variants on QT interval in African Americans. Circ Cardiovasc Genet. 2012;5(6):647–55.
94. Manini AF, Stimmel B, Vlahov D. Racial susceptibility for QT prolongation in acute drug overdoses. J Electrocardiol. 2014;47(2):244–50.
95. Olatunde A, Price Evans DA. Blood quinidine levels and cardiac effects in white British and Nigerian subjects. Br J Clin Pharmacol. 1982;14(4):513–8.
96. Shin JG, Kang WK, Shon JH, Arefayene M, Yoon YR, Kim KA, et al. Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects. Br J Clin Pharmacol. 2007;63(2):206–15.
97. Malik M, Hnatkova K, Schmidt A, Smetana P. Electrocardiographic QTc changes due to moxifloxacin infusion. J Clin Pharmacol. 2009;49(6):674–83.
98. Kannankeril PJ, Norris KJ, Carter S, Roden DM. Factors affecting the degree of QT prolongation with drug challenge in a large cohort of normal volunteers. Heart Rhythm. 2011;8(10):1530–4.
99. Taubel J, Ferber G, Lorch U, Batchvarov V, Savelieva I, Camm AJ. Thorough QT study of the effect of oral moxifloxacin on QTc interval in the fed and fasted state in healthy Japanese and Caucasian subjects. Br J Clin Pharmacol. 2014;77(1):170–9.
100. Sugiyama A, Nakamura Y, Nishimura S, Adachi-Akahane S, Kumagai Y, Gayed J, et al. Comparison of the effects of levofloxacin on QT/QTc interval assessed in both healthy Japanese and Caucasian subjects. Br J Clin Pharmacol. 2012;73(3):455–9.
101. Shah RR. Pharmacogenetics in drug regulation: promise, potential and pitfalls. Philos Trans R Soc Lond B Biol Sci. 2005;360(1460):1617–38.
102. Kiezun A, Garimella K, Do R, Stitziel NO, Neale BM, McLaren PJ, et al. Exome sequencing and the genetic basis of complex traits. Nat Genet. 2012;44(6):623–30.
103. Tester DJ, Ackerman MJ. The molecular autopsy: should the evaluation continue after the funeral? Pediatr Cardiol. 2012;33(3):461–70.
104. Kamei S, Sato N, Harayama Y, Nunotani M, Takatsu K, Shiozaki T, et al. Molecular analysis of potassium ion channel genes in sudden death cases among patients administered psychotropic drug therapy: are polymorphisms in LQT genes a potential risk factor? J Hum Genet. 2014;59(2):95–9.
105. van Opstal JM, Schoenmakers M, Verduyn SC, de Groot SH, Leunissen JD, van Der Hulst FF, et al. Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation. 2001;104(22):2722–7.
106. Thomsen MB, Matz J, Volders PG, Vos MA. Assessing the proarrhythmic potential of drugs: current status of models and surrogate parameters of torsades de pointes arrhythmias. Pharmacol Ther. 2006;112(1):150–70.
107. de Bruyne MC, Kors JA, Hoes AW, Klootwijk P, Dekker JM, Hofman A, et al. Both decreased and increased heart rate variability on the standard 10-second electrocardiogram predict cardiac mortality in the elderly: the Rotterdam Study. Am J Epidemiol. 1999;150(12):1282–8.
108. Niemeijer MN, van den Berg ME, Eijgelsheim M, van Herpen G, Stricker BH, Kors JA, et al. Short-term QT variability markers for the prediction of ventricular arrhythmias and sudden cardiac death: a systematic review. Heart. 2014;100(23):1831–6.
109. Wang B, Canestaro WJ, Choudhry NK. Clinical evidence supporting pharmacogenomic biomarker testing provided in US Food and Drug Administration drug labels. JAMA Intern Med. 2014;174(12):1938–44.
110. National Center for Biotechnology Information (NCBI) Gene; Available from: http://www.ncbi.nlm.nih.gov/gene/. Cited 10 Mar 2015.